Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.
Empyrean Neuroscience has raised $22.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Empyrean Neuroscience's investors include Spore Partners.
Empyrean Neuroscience is headquartered in New York, United States.
Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.
Empyrean Neuroscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Empyrean Neuroscience — Funding & Investors." VCBacked, October 18, 2022, https://www.vcbacked.co/company/empyrean-neuroscience. Accessed September 30, 2026.
VCBacked. (2022). Empyrean Neuroscience — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/empyrean-neuroscience
{{cite web |title=Empyrean Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/empyrean-neuroscience |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated